

# Association between IL-1RN gene polymorphisms and susceptibility to ankylosing spondylitis: a large Human Genome Epidemiology review and meta-analysis

## G.X. Jin, J.Z. Duan, W.L. Guo, L. Li, S.Q. Cui and H. Wang

Department of Orthopedics Surgery, Shengjing Hospital of China Medical University, Shenyang, China

Corresponding author: H. Wang E-mail: cmu wh@163.com

Genet. Mol. Res. 12 (2): 1720-1730 (2013) Received May 14, 2012 Accepted March 2, 2013 Published May 21, 2013 DOI http://dx.doi.org/10.4238/2013.May.21.3

ABSTRACT. We made a Human Genome Epidemiology review and meta-analysis to examine a possible association between interleukin-1 receptor antagonist (IL-1RN) polymorphisms and susceptibility to ankylosing spondylitis (AS). Studies of IL-1RN polymorphisms and susceptibility to AS were found by searching the Pubmed, Cochrane library, Embase, Web of Science, Springerlink, CNKI, and CBM databases. Data were extracted by 2 independent reviewers. The metaanalysis was performed with the Review Manager Version 5.1.6 and STATA Version 12.0 software. The odds ratio (OR) and 95% confidence intervals (95%CI) were calculated based on the extracted data. Thirteen studies with 5391 AS cases and 5239 healthy controls were retrieved. Seven IL-1RN polymorphisms were addressed, including rs30735, rs31017, rs419598, rs315951, rs315952, rs27810, and VNTR. Metaanalysis showed that the rs30735\*C allele/carrier, the rs31017\*G carrier and the rs315952\*T carrier were positively and significantly associated with susceptibility to AS (OR = 1.45, 95%CI = 1.19-1.76; OR = 1.73,95%CI = 1.34-2.24; OR = 1.30, 95%CI = 1.01-1.69; OR = 1.54, 95%CI = 1.16-2.04). A subgroup analysis based on ethnicity revealed significant positive associations between the rs30735\*C allele/carrier and the

Genetics and Molecular Research 12 (2): 1720-1730 (2013)

rs31017\*G allele and susceptibility to AS in both Caucasian and Asian populations, while the positive association between the rs315952\*T carrier and AS susceptibility was significant only in Asian populations (OR = 1.54, 95%CI = 1.16-2.04). This meta-analysis suggests that IL-1RN polymorphisms are involved in the pathogenesis of AS. The rs30735\*C allele/carrier, and the rs31017\*G allele may be risk factors for ankylosing spondylitis in Caucasians and Asians, while the rs315952\*T carrier is associated with susceptibility to this disease only in Asians.

**Key words:** Interleukin-1 receptor antagonist; Genetic polymorphisms; Ankylosing spondylitis; Susceptibility; Meta-analysis

## **INTRODUCTION**

Ankylosing spondylitis (AS) is one of the most common chronic spondyloarthropathies and is characterized by inflammation of the spine and sacroiliac joints; it can be an outcome of any of the spondyloarthropathy subtypes (El Maghraoui, 2011). AS is a common cause of inflammatory arthritis, with a prevalence of 0.25% in European populations (Reveille et al., 2010); men are affected at half the rate of women (Feldtkeller et al., 2003). Most patients with AS develop the first symptoms at 25-45 years of age (Braun and Sieper, 2007). Although AS is the product of an interaction between environmental triggers, susceptibility genes, gender, age, and ethnicity (Zhang et al., 2011), the precise pathogenic mechanism of AS is unknown. Previous studies have confirmed HLA-B27 as the major genetic key associated with AS (16-40%) (Peloso et al., 2011). However, HLA-B27 cannot explain all patients with AS, as only 5% of HLA-B27-positive individuals develop AS (Duan et al., 2012), indicating that there are other contributing causes.

Familial clustering has often been considered as an indication of genetic factors in disease etiology (Baraliakos et al., 2008). The interleukin-1 (IL-1) family gene cluster consists of 3 genes: IL-1A, IL-1B, and IL-1RN. IL-1A and -B encode pro-inflammatory cytokines IL-1α and IL-1β, which have been implicated in joint destruction. IL-1RN encodes IL-1 receptor antagonist (IL-1Ra), an anti-inflammatory non-signaling molecule that prevents IL-1 receptor signaling by competitive inhibition (van der Paardt et al., 2002; Maksymowych et al., 2003; Timms et al., 2004; Kim et al., 2005). Several studies have addressed the association between members of the IL-1 gene cluster and AS susceptibility (Laval et al., 2001). Most of these studies focused on the IL-1A, IL-1B, and IL-1RN genes, especially the IL-1RN variable number of tandem repeat polymorphism (VNTR). None of these studies demonstrated a connection between AS susceptibility and the IL-1 gene cluster. Recently, 2 independent studies suggested associations between VNTR\*2 in intron 2 and single-nucleotide polymorphisms (SNPs) in exon 6 of the IL-1RN gene (McGarry et al., 2001; Maksymowych et al., 2003) and AS susceptibility. However, some of these studies yielded conflicting results (Guo et al., 2010). Since we could not draw definitive conclusions about IL-1RN polymorphisms and AS susceptibility from these studies, we decided to perform a meta-analysis.

#### MATERIAL AND METHODS

#### Literature search

Pubmed, Cochrane library, Embase, Web of Science, Springerlink, CNKI, and CBM

Genetics and Molecular Research 12 (2): 1720-1730 (2013)

databases were searched (last search was updated on March 30, 2012) to identify relevant studies. The search terms included ["ankylosing spondylitis" or "spondylitis, ankylosing" (Mesh)] and ["polymorphism, single nucleotide" or "polymorphism, genetic" (Mesh)] and ["Interleukin-1 receptor antagonist" or "IL-1RN" (Mesh)]. References in eligible studies or textbooks were also reviewed.

#### Inclusion and exclusion criteria

The included studies had to meet the following criteria: the type of study had to be a case-control study; the study must have focused on associations between IL-1RN polymorphisms and AS susceptibility; the diagnosis principle of AS had to strictly match with the modified New York criteria (1984); the frequencies of alleles or genotypes in case and control groups had to be capable of extraction; and the publication had to be in English or Chinese. Studies were excluded when they were not case-control studies of IL-RN polymorphisms and susceptibility to AS if they were based on incomplete data or if useless or overlapping data were reported.

#### **Data extraction**

Using a standardized form, data from published studies were extracted independently by 2 reviewers (W.L. Guo and L. Li) to collect information including: first author, year of publication, country, language, ethnicity, study design, diagnostic criteria, source of cases and controls, number of cases and controls, mean age, sample, detection methods, polymorphism genotype frequency, and evidence of Hardy-Weinberg equilibrium (HWE) in controls. In cases of conflicting evaluations, an agreement was reached following a discussion with a third reviewer (H. Wang).

#### Quality assessment of included studies

Two reviewers (G.X. Jin and J.Z. Duan) independently assessed the quality of the papers according to modified STROBE quality score systems (Vandenbroucke et al., 2007; Zhang et al., 2011). Forty quality appraisal items were used in this meta-analysis, with scores ranging from 0 to 40. Scores of 0-20, 20-30, and 30-40 were defined as low, moderate, and high quality, respectively. Disagreement was resolved by discussion.

#### **Statistical analysis**

Allele or genotype frequencies of IL-1RN SNPs were determined by the allele counting method. The odds ratio (OR) and 95% confidence intervals (95%CI) were calculated with Review Manager Version 5.1.6 (provided by the Cochrane Collaboration, available at: http:// ims.cochrane.org/revman/download) and STATA Version 12.0 (Stata Corp, College Station, TX, USA). Between-study variations and heterogeneities were estimated using the Cochran Q-statistic (Zintzaras and Ioannidis, 2005; Peters et al., 2006);  $P \le 0.05$  was considered to represent statistically significant heterogeneity. We also quantified the effect of heterogeneity by using a recently developed method called I<sup>2</sup>, which ranges from 0 to 100% and represents the proportion of inter-study variability that can be attributed to heterogeneity, a random-effect model was generated for meta-analysis. Otherwise, the fixed-effect model was used. To establish the effect of heterogeneity on meta-analysis conclusions, subgroup analysis was performed. The  $\chi^2$  test was used to determine whether the control genotype frequencies were in HWE. Fun-

Genetics and Molecular Research 12 (2): 1720-1730 (2013)

nel plots have often been used to detect publication bias. However, due to limitations of varied sample size and subjective reviews, the Egger linear regression test (Higgins and Thompson, 2002), which measures funnel plot asymmetry using a natural logarithm scale of OR, was used to evaluate publication bias. Publication bias was considered to be significant at P < 0.1.

#### RESULTS

#### The characteristics of included studies

According to the inclusion criteria, 13 studies (McGarry et al., 2001; van der Paardt et al., 2002; Maksymowych et al., 2003; Timms et al., 2004; Kim et al., 2005; Chou et al., 2006; Lin et al., 2006; Maksymowych et al., 2006; Yang et al., 2007; Agrawal et al., 2008; Liu et al., 2008; Sims et al., 2008; Guo et al., 2010) were included and 53 were excluded. A flow chart of the study selection process is shown in Figure 1. The total number of AS cases and healthy controls were 5391 and 5239 in the 13 case-control studies that evaluated the relationship between IL-1RN polymorphisms and AS susceptibility. Publication year ranged from 2001 to 2010. All patients fulfilled the 1984 modified New York criteria for diagnosis of AS. Seven IL-1RN polymorphisms were addressed, including rs30735, rs31017, rs419598, rs315951, rs315952, rs27810, and VNTR. The most common polymorphisms were VNTR, rs315952, rs31017, and rs30735. The HWE test was conducted for the controls in every study. Four studies of mainly Asian populations were not in HWE (P < 0.05) (McGarry et al., 2001; Lin et al., 2006; Agrawal et al., 2008; Liu et al., 2008); all others were in HWE (P > 0.05). All quality scores were >20 (moderately to high quality). The characteristics and methodological quality of the studies included are summarized in Table 1.





#### Association between IL-1RN polymorphisms and AS risk

A summary of the meta-analysis findings of the association between IL-1RN polymorphisms and AS susceptibility is provided in Table 2. The meta-analysis showed that the rs30735\*C allele/carrier, the rs31017\*G carrier and the rs315952\*T carrier had positive associations with AS susceptibility (OR = 1.45, 95%CI = 1.19-1.76, P = 0.0002; OR = 1.73, 95%CI = 1.34-2.24, P < 0.0001; OR = 1.30, 95%CI = 1.01-1.69, P = 0.04; OR = 1.54, 95%CI = 1.16-2.04, P = 0.003, respectively). However, there were no significant associations for rs27810\*C allele/carrier, rs31017\*G

Genetics and Molecular Research 12 (2): 1720-1730 (2013)

First author	Year	Country	Ethnicity	Language	Case	No.	Sample	Detection	SNP	HV	VE test
					AS	Control				Р	Test
McGarrry et al.	2001	UK	Caucasian	English	182	191	Blood	PCR-RFLP	VNTR (X/2)	<0.05	Non-HWE
van der Paardt et al.	2002	Netherlands	Caucasian	English	104	104	Blood	PCR-RFLP	VNTR (X/2)	0.05	HWE
Maksymowych et al.	2003	Canada	Caucasian	English	382	490	Blood	MassArray	rs27810 (T/C)	0.63	HWE
									rs30735 (T/C)	0.48	HWE
	1000	1.117		-	007				rs31017 (C/G)	050	HWE
Limms et al.	2004	UK	Caucasian	English	480	10/	Blood	MassArray	VNIK (X/2)	0.21	HWE
Kim et al.	2002	Canada	Caucasian	English	213	364	Blood	PCK-KFLP	VNTK (X/2)	0.83	HWE
Chou et al.	2006	China	Asian	English	189	193	Blood	MassArray	rs41938 (1/C)	0.73	HWE
									VNTR (X/2)	0.68	HWE
									rs315952 (C/T)	0.29	HWE
									rs315951 (C/G)	0.28	HWE
Lin et al.	2006	China	Asian	Chinese	100	92	Blood	PCR-SSP	VNTR (X/2)	<0.05	Non-HWE
Maksymowych et al.	2006	Canada	Caucasian	English	394	500	Blood	PCR-SSP	rs419598 (T/C)	06.0	HWE
									rs315951 (C/G)	0.99	HWE
Yang et al.	2007	China	Asian	Chinese	48	33	Blood	Genechips	rs31017 (C/G)	0.78	HWE
									rs30735 (T/C)	0.10	HWE
Agrawal et al.	2008	India	Asian	English	162	111	Blood	PCR-SSP	VNTR (X/2)	<0.05	Non-HWE
Liu et al.	2008	China	Asian	Chinese	162	162	Blood	PCR-RFLP	rs419598 (T/C)	<0.05	Non-HWE
									rs315952 (C/T)	0.89	HWE
Sims et al.	2008	Australia	Caucasian	English	2675	2592	Blood	PCR-RFLP	rs419598 (T/C)	0.98	HWE
									VNTR (X/2)	0.98	HWE
									rs315952 (C/T)	0.98	HWE
									rs315951 (C/G)	0.99	HWE
Guo et al.	2010	China	Asian	English	240	240	Blood	PCR-RFLP	rs419598 (T/C)	0.48	HWE
									VNTR (X/2)	0.10	HWE
									rs315952 (C/T)	0.75	HWE

# G.X. Jin et al.

Genetics and Molecular Research 12 (2): 1720-1730 (2013)

allele, rs315951\*G allele/carrier, rs315952\*T allele, rs419598\*C allele/carrier, and VNTR\*2 allele/carrier (all P > 0.05). In the subgroup analysis based on ethnicity, subjects were divided into Caucasian and Asian populations. There were positive associations between the rs30735\*C allele/ carrier, and the rs31017\*G allele and AS susceptibility in Caucasian populations (OR = 1.40, 95%CI = 1.14-1.71, P = 0.001; OR = 1.66, 95%CI = 1.27-2.18, P = 0.0002; OR = 1.24, 95%CI = 1.01-1.53, P=0.04, respectively). Similarly, the rs30735\*C allele/carrier and the rs31017\*G allele were significantly associated with AS susceptibility in Asian populations (OR = 2.27, 95%CI = 1.05-4.91, P = 0.04; OR = 2.74, 95%CI = 1.11-6.77, P = 0.03; OR = 2.67, 95%CI = 1.40-5.10, P = 0.003, respectively). In addition, a positive association was found between the rs315952\*T carrier and AS susceptibility only in Asian populations (OR = 1.54, 95% CI = 1.16-2.04, P = 0.003). Nevertheless, rs27810\*C allele/carrier, rs315951\*G allele/carrier, rs315952\*T allele, rs419598\*C allele/carrier, and VNTR\*2 allele/carrier also showed no association with AS susceptibility in Caucasian and Asian populations (all P > 0.05). Sensitivity analysis was performed by sequential omission of non-HWE studies. The significance of pooled OR in all individual analyses and subgroup analyses was not influenced excessively by omitting any single study. The positive associations between IL-1RN polymorphisms and AS susceptibility are shown in Figure 2.

Polymorphisms	Eligible studies	AS cases	Controls	OR (95%CI)	Р	Heterogeneity test	Effect model
Rs27810*C allele	1	225/764	312/980	0.89 (0.73-1.10)	0.28	-	Fixed
Caucasian	1	225/764	312/980	0.89 (0.73-1.10)	0.28	-	
Rs27810*C carrier	1	203/382	260/490	1.00 (0.77-1.31)	0.98	-	Fixed
Caucasian	1	203/382	260/490	1.00 (0.77-1.31)	0.98	-	
Rs30735*C allele	2	304/876	285/1048	1.45 (1.19-1.76)	0.0002	$P = 0.24, I^2 = 29\%$	Fixed
Caucasian	1	272/776	274/984	1.40 (1.14-1.71)	0.001	-	
Asian	1	32/100	11/64	2.27 (1.05-4.91)	0.04	-	
Rs30735*C carrier	2	269/438	252/525	1.73 (1.34-2.24)	< 0.0001	$P = 0.30, I^2 = 6\%$	Fixed
Caucasian	1	237/388	239/492	1.66 (1.27-2.18)	0.0002	-	
Asian	1	32/50	13/33	2.74 (1.11-6.77)	0.03	-	
Rs31017*G allele	2	310/862	300/1042	1.71 (0.82-3.58)	0.15	$P = 0.03$ , $I^2 = 79\%$	Random
Caucasian	1	252/766	276/976	1.24 (1.01-1.53)	0.04	-	
Asian	1	58/96	24/66	2.67 (1.40-5.10)	0.003	-	
Rs31017*G carrier	2	247/431	260/521	1.30 (1.01-1.69)	0.04	$P = 0.28$ , $I^2 = 15\%$	Fixed
Caucasian	1	210/383	240/488	1.25 (0.96-1.64)	0.10	-	
Asian	1	37/48	20/33	2.19 (0.83-5.77)	0.11	-	
Rs315951*G allele	3	1858/3362	1955/3470	0.93 (0.79-1.10)	0.38	$P = 0.12, I^2 = 54\%$	Random
Caucasian	2	1716/2982	1784/3078	0.99 (0.86-1.14)	0.86	$P = 0.22$ , $I^2 = 34\%$	
Asian	1	142/380	171/392	0.77 (0.58-1.03)	0.08	-	
Rs315951*G carrier	1	117/190	130/196	0.81 (0.54-1.23)	0.33	-	Fixed
Asian	1	117/190	130/196	0.81 (0.54-1.23)	0.33	-	
Rs315952*T allele	4	2599/4424	2350/4140	1.08 (0.99-1.18)	0.07	$P = 0.69, I^2 = 0\%$	Fixed
Caucasian	1	1972/3246	1774/3004	1.07 (0.97-1.19)	0.17	-	
Asian	3	627/1178	576/1136	1.11 (0.95-1.31)	0.20	$P = 0.52$ , $I^2 = 0\%$	
Rs315952*T carrier	3	481/589	423/568	1.54 (1.16-2.04)	0.003	$P = 0.44, I^2 = 0\%$	Fixed
Asian	3	481/589	423/568	1.54 (1.16-2.04)	0.003	$P = 0.44$ , $I^2 = 0\%$	
Rs419598*C allele	5	1198/5222	1137/5122	1.03 (0.77-1.38)	0.83	$P = 0.0006$ , $I^2 = 80\%$	Random
Caucasian	2	1080/4046	1031/3944	1.01 (0.85-1.20)	0.91	$P = 0.13$ , $I^2 = 56\%$	
Asian	3	118/1176	106/1178	1.05 (0.44-2.47)	0.91	$P = 0.0002, I^2 = 88\%$	
Rs419598*C carrier	3	110/588	95/589	1 14 (0 42-3 10)	0.80	$P < 0.0001$ $I^2 = 90\%$	Random
Asian	3	110/588	95/589	1.14 (0.42-3.10)	0.80	$P < 0.0001, I^2 = 90\%$	
VNTR*2 allele	9	1273/5904	1115/5344	1.10 (0.85-1.41)	0.46	$P < 0.0001, I^2 = 77\%$	Random
Caucasian	5	1115/4534	987/4078	1.08 (0.83-1.40)	0.58	$P = 0.004$ , $I^2 = 74\%$	
Asian	4	158/1370	128/1266	1 18 (0 59-2 34)	0.64	$P = 0.0003$ $I^2 = 84\%$	
VNTR*2 carrier	7	447/1451	243/1095	1.39 (0.86-2.24)	0.18	$P < 0.0001$ , $I^2 = 81\%$	Random
Caucasian	3	309/766	134/462	1.50 (0.89-2.51)	0.12	$P = 0.05$ $I^2 = 67\%$	
Asian	4	138/685	109/633	1 33 (0 55-3 21)	0.53	$P < 0.0001$ $I^2 = 88\%$	

Cases and controls are reported as number of individuals/total individuals. AS = ankylosing spondylitis; OR = odds ratios; 95%CI = 95% confidence interval.

Genetics and Molecular Research 12 (2): 1720-1730 (2013)

G.X. Jin et al.

Study or Subgroup	AS gro Events	up Total	Control Events	group Total	Weight	Odds Ratio M-H, Fixed, 95%CI	Odds Ratio M-H, Fixed, 95%CI
Caucasian				. otdi			
3 Maksymowych et al., 2003 Subtotal (95%Cl)	272	776 776	274	984 984	94.5% 94.5%	1.40 [1.14, 1.71] 1.40 [1.14, 1.71]	<b>◆</b>
otal events leterogeneity: Not applicable	272		2/4				
est for overall effect: Z = 3.24	(P = 0.00	1)					
Isian							
9 Yang et al., 2007 Subtotal (95%CI)	32	100	11	64 64	5.5%	2.27 [1.05, 4.91]	•
otal events	32	100	11	04	5.576	2.27 [1.05, 4.51]	-
leterogeneity: Not applicable fest for overall effect: Z = 2.07	(P = 0.04	)					
Total (95%CI)		876		1048	100.0%	1.45 [1.19, 1.76]	•
Fotal events	304		285				
Heterogeneity: Chi* = 1.40, d.t. Fest for overall effect: Z = 3.69 Fest for subgroup differences:	= 1 (P = 0. (P = 0.00 Chi <sup>2</sup> = 1.4	24); I* 02) 0. d.f.=	= 29% 1 (P = 0.2	4), l <sup>2</sup> = 2	8.7%		0.01 0.1 1 10 1 Favors control Favors AS
s30735*C carrier							
Study or Subgroup	AS gro Evente	up Total	Control Events	group Total	Weight	Odds Ratio	Odds Ratio
Caucasian	Lyents	rotel	Lyents	Total	reight		
03 Maksymowych et al., 2003	237	388	239	492	93.6%	1.66 [1.27, 2.18]	
Fotal events	237	აგგ	239	492	93.6%	1.00 [1.27, 2.18]	•
Heterogeneity: Not applicable Fest for overall effect: Z = 3.69	(P = 0.00	02)	200				
Asian							
9 Yang et al., 2007	32	50	13	33	6.4%	2.74 [1.11, 6.77]	-
Subtotal (95%CI)		50		33	6.4%	2.74 [1.11, 6.77]	•
Fotal events	32		13				
Test for overall effect: Z = 2.18	(P = 0.03	)					
Fotal (95%CI)		438		525	100.0%	1.73 [1.34, 2.24]	•
Fotal events	269	201.12	252				
Heterogeneity: Chi <sup>e</sup> = 1.07, d.f. Test for overall effect: 7 = 4 16	= 1 (P = 0.) (P < 0.00)	30); I* 01)	= 6%				0.01 0.1 1 10 1
		_					E
Test for subaroup differences:	Chi <sup>2</sup> = 1.0	7. df =	1 (P = 0.3	0). I <sup>2</sup> = 6	.3%		Favors control Favors AS
Test for suboroup differences:	Chi <sup>2</sup> = 1.0	7. df =	1 (P = 0.3 Control g	0). I <sup>2</sup> = 6	.3%	Odds Ratio	Favors control Favors AS Odds Ratio
Test for subaroup differences: Rs31017*G allele Study or Subgroup	Chi <sup>2</sup> = 1.0 AS grou Events	7. df = ip Total	1 (P = 0.3 Control g Events	0). I <sup>2</sup> = 6 roup Total	.3% Weight	Odds Ratio M-H. Random. 95%C	Favors control Favors AS Odds Ratio
Test for subaroup differences: Rs31017*G allele Study or Subgroup Caucasian 3 Makeymowych et al. 2003	Chi <sup>2</sup> = 1.0 AS grou Events 252	7. df = ip Total	1 (P = 0.3 Control g Events 276	0). I <sup>2</sup> = 6 roup <u>Total</u>	3% Weight	Odds Ratio M-H. Random. 95%C	Favors control     Favors AS       Odds Ratio       I     M-H. Random, 95%CI
Test for subgroup differences: - Rs31017°G allele Study or Subgroup Caucasian 30 Maksymowych et al., 2003 Subtotal (95%CI)	Chi <sup>2</sup> = 1.0 AS grou Events 252	7. df = ip Total 766 766	1 (P = 0.3 Control g Events 276	0). I <sup>2</sup> = 6 roup <u>Total</u> 976 976	3% Weight 58.4% 58.4%	Odds Ratio M-H. Random, 95%C 1.24 [1.01, 1.53] 1.24 [1.01, 1.53]	Favors control     Favors AS       Odds Ratio       M-H. Random, 95%Cl
Test for subgroup differences: Rs31017*G allele Study or Subgroup Caucasian 33 Maksymowych et al., 2003 Subtotal (95%CI) Total events	Chi <sup>2</sup> = 1.0 AS grou Events 252 252	7. df = Ip Total 766 766	1 (P = 0.3 Control g Events 276 276	0). I <sup>2</sup> = 6 roup <u>Total</u> 976 976	3% Weight 58.4% 58.4%	Odds Ratio M-H. Random, 95%C 1.24 [1.01, 1.53] 1.24 [1.01, 1.53]	Odds Ratio       M-H. Random, 95%Cl
Test for suboroun differences : <b>R\$31017'G allele</b> Study or Subgroup Zaucasian 30 Maksymowych et al., 2003 Subtota (95%CI) Total events reterogeneity: Not applicable Test for overall effect: Z = 2.08	Chi <sup>2</sup> = 1.0 AS grou Events 252 252 (P = 0.04)	7. df = 10 10 10 10 10 10 10 10 10 10	1 (P = 0.3 Control g Events 276 276	0). I <sup>2</sup> = 6 roup <u>Total</u> 976 976	3% Weight 58.4% 58.4%	Odds Ratio <u>M-H. Random. 95%C</u> 1.24 [1.01, 1.53] 1.24 [1.01, 1.53]	Codds Ratio
Test for suboroun differences: - Res1017°G allele Study or Subgroup Zaucasian 33 Maksymowych et al., 2003 Subtata (18% zaucasian detorogeneity: Not applicable Test for overall effect: Z = 2.08   Stain Dy Yang et al., 2007	Chi <sup>2</sup> = 1.0 AS grou Events 252 252 (P = 0.04) 58	7. df = 10 10 10 10 10 10 10 10 10 10	1 (P = 0.3 Control g <u>Events</u> 276 276 276	0). I <sup>2</sup> = 6 roup <u>Total</u> 976 976 66	.3% <u>Weight</u> 58.4% 58.4% 41.6%	Odds Ratio <u>M-H. Random, 95%C</u> 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 2.67 [1.40, 5.10]	Codds Ratio
Test for suboroun differences: - Re31017'G allele Study or Subgroup Zaucasian 13 Maksymowych et al., 2003 Subtotal (85%CI) Fotal events rest for overall effect Z = 2.08 Kalan 19 Yang et al., 2007 Subtotal (85%CI)	Chi <sup>2</sup> = 1.0 AS grou Events 252 252 (P = 0.04) 58	7. df = 10 10 10 10 10 10 10 10 10 10	1 (P = 0.3 Control g Events 276 276 276	0). I <sup>2</sup> = 6 roup <u>Total</u> 976 976 976 66 66	.3% Weight 58.4% 58.4% 41.6% 41.6%	Odds Ratio M.H. Random. 95%C 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10]	Favors control Favors AS Odds Ratio M-H. Random. 95%CI
Test for suboroun differences: <b>Rs31017'G allele</b> Study or Subgroup Jaucesian J3 Maksymowych et al., 2003 Subotal (95%CI) Total events Test for overall effect. Z = 2.08 <b>Stan</b> J9 Yang et al., 2007 Subotat (95%CI) Total events	Chi <sup>2</sup> = 1.0 AS grou Events 252 252 (P = 0.04) 58 58	7. df = 10 10 10 10 10 10 10 10 10 10	1 (P = 0.3 Control g <u>Events</u> 276 276 24 24 24	0). I <sup>2</sup> = 6 roup <u>Total</u> 976 976 976 66 66	.3% Weight 58.4% 58.4% 41.6% 41.6%	Odds Ratio M.H. Random, 95%C 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10]	Favors control Favors AS Odds Ratio M-H. Random, 95%CI
Test for subaroun differences: - Rs31017'G allele Study or Subgroup Zaucasian 33 Maksymowych et al., 2003 Subtotal (95%CI) Total events Heterogeneity: Not applicable Test for overall effect: Z = 2.8 Subtotal (95%CI) Total events Fotal events Fotal events Heterogeneity: Not applicable Test for overall effect: Z = 2.89	Chi <sup>2</sup> = 1.0 AS grou Events 252 252 (P = 0.04) 58 58 (P = 0.003	7. df = 10 10 10 10 10 10 10 10 10 10	1 (P = 0.3 Control g <u>Events</u> 276 276 24 24	0). I <sup>2</sup> = 6 roup <u>Total</u> 976 976 66 66	.3% Weight 58.4% 58.4% 41.6% 41.6%	Odds Ratio M-H. Random. 35%C 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10]	Favors control Favors AS Odds Ratio M-H. Random, 95%CI
Test for suboroun differences: - Rs31017°G allele Study or Subgroup Zaucasian J3 Maksymowych et al., 2003 Subtotal (95%) Total events -teterogeneity: Not applicable Test for overall effect: Z = 2.98 Total events -teterogeneity: Not applicable Test for overall effect: Z = 2.98 Total effect: Z = 2.98	Chi <sup>2</sup> = 1.0 AS grou Events 252 252 (P = 0.04) 58 58 (P = 0.003	7. df = 10 10 10 10 10 10 10 10 10 10	1 (P = 0.3 Control g Events 276 276 24 24 24	0). I <sup>2</sup> = 6 roup <u>Total</u> 976 976 976 66 66 66 66	.3% <u>Weight</u> 58.4% 58.4% 41.6% 41.6% 100.0%	Odds Ratio M-H. Random. 35%C 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10]	Avors control Favors AS
Test for suboroun differences: - <b>Rs31017'G allele</b> Study or Subgroup Caucasian 33 Maksymowych et al., 2003 Subtota (95% CI) Fotal events Heterogeneity: Not applicable Test for overall effect: Z = 2.08   Asian 09 Yang et al., 2007 Subtota (95% CI) Total events Heterogeneity: Not applicable Test for overall effect: Z = 2.98   Total (95% CI)	Chi <sup>2</sup> = 1.0 AS grou Events 252 252 (P = 0.04) 58 58 (P = 0.003 310	7. df = 10 10 10 10 10 10 10 10 10 10	1 (P = 0.3 Control g Events 276 276 24 24 24 300	0). I <sup>2</sup> = 6 Toup Total 976 976 976 66 66 66	.3% Weight 58.4% 58.4% 41.6% 41.6%	Odds Ratio M-H. Random, 95%C 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10] 1.71 [0.82, 3.58]	Favors control Favors AS Odds Ratio M-H. Random. 95%CI
Test for suboroun differences: - <b>ks31017'G allele</b> Study or Subgroup Zaucasian 33 Maksymowych et al., 2003 Subtota (195%) Total events -tetorogenei(y: Not applicable Test for overall effect: Z = 2.08 Statan Dy Yang et al., 2007 Subtota (195%CI) Total events -tetorogenei(y: Not applicable Test for overall effect: Z = 2.98 Total (95%CI) Total events -tetorogenei(y: Tau <sup>2</sup> = 0.23; Chi -test for overall effect: Z = 1.42]	Chi <sup>2</sup> = 1.0 AS grou Events 252 252 (P = 0.04) 58 58 (P = 0.003 310 <sup>2</sup> = 4.87, d (P = 0.15)	7. df = 10 10 10 10 10 10 10 10 10 10	1 (P = 0.3 Control g Events 276 276 24 24 24 24 24 24 24	0). I <sup>2</sup> = 6 roup <u>Total</u> 976 976 976 66 66 66 1042 I <sup>2</sup> = 79%	.3% Weight 58.4% 58.4% 41.6% 41.6% 100.0%	Odds Ratio M-H. Random. 95%C 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10] 1.71 [0.82, 3.58]	Pavors control Favors AS
Test for suboroun differences: Rs31017'G allele Study or Subgroup Saucasian 33 Maksymowych et al., 2003 Subtota (18%): At applicable Test for overall effect: Z = 2.08 State Total events Heterogeneity: Not applicable Test for overall effect: Z = 2.98 Total events Heterogeneity: Total applicable Test for overall effect: Z = 2.98 Total events Heterogeneity: Tau <sup>2</sup> = 0.23; Chi Test for suboroun differences. N Rs31017'G carrier	Chi <sup>2</sup> = 1.0 AS grou Events 252 252 (P = 0.04) 58 58 (P = 0.003 310 <sup>2</sup> = 4.87, d (P = 0.15) Not applica	7. df = 10 10 10 10 10 10 10 10 10 10	1 (P = 0.3 Control g Events 276 276 24 24 24 24 24 24 24	0).   <sup>2</sup> = 6 roup <u>Total</u> 976 976 66 66 66 1042 <sup>2</sup> = 79%	.3% Weight 58.4% 58.4% 41.6% 41.6%	Odds Ratio M-H. Random. 55%C 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10] 1.71 [0.82, 3.58]	Pavors control Favors AS
Test for suboroun differences: - <b>Rs31017'G allele</b> Study or Subgroup Study or Subgroup Studsawmowych et al., 2003 Subtota (195% ct) Total events Heterogeneity: Not applicable Test for overall effect: Z = 2.08 Asian Dy Yang et al., 2007 Subtotal (95% Ct) Total events Heterogeneity: Nat applicable Test for overall effect: Z = 1.28 Total (95% Ct) Total events Heterogeneity: Tau <sup>2</sup> = 0.23; Chi Test for overall effect: Z = 1.21 Test for subbroup differences: N Rs31017'G carrier	Chi <sup>2</sup> = 1.0 AS grou Events 252 252 (P = 0.04) 58 58 (P = 0.003 310 <sup>2</sup> = 4.87, d (P = 0.15) Not applications AS groups	7. df = 10 10 10 10 10 10 10 10 10 10	1 (P = 0.3 Control g Events 276 276 24 24 24 24 24 24 Control 3 276 276 276 276 276 276 276 276	0).   <sup>2</sup> = 6 roup <u>Total</u> 976 976 66 66 66 1042   <sup>2</sup> = 79% group	.3% Weight 58.4% 58.4% 41.6% 41.6%	Odds Ratio M-H. Random, 95%C 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10] 1.71 [0.82, 3.58] 0.645 Ratio	Pavors control Pavors AS
Test for suboroun differences: - Re31017'G allele Study or Subgroup Zaucasian J3 Maksymowych et al., 2003 Subtotal (85%CI) Total events Heterogeneity: Not applicable Test for overall offect: Z = 2.08 Subtotal (85%CI) Total events Heterogeneity: Nat applicable Test for overall offect: Z = 2.98 Total (95%CI) Total events Heterogeneity: Tau <sup>2</sup> = 0.23, Chi Test for overall offect: Z = 1.42 Test for overall offect: Z = 1	Chi <sup>2</sup> = 1.0 AS grou- Events 252 252 (P = 0.04) 58 58 (P = 0.003 <sup>2</sup> = 4.87, d (P = 0.15) Not application AS groups Events	7. df = 10 10 10 10 10 10 10 10 10 10	1 (P = 0.3 Control g Events 276 276 24 24 24 24 24 24 24 Control g Events	0).   <sup>2</sup> = 6 roup Total 976 976 976 66 66 66 1042 <sup>2</sup> = 79% group Total	.3% Weight 58.4% 58.4% 41.6% 41.6% 100.0% Weight	Odds Ratio M-H. Random, 95%C 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10] 1.71 [0.82, 3.58] 0.dds Ratio M-H. Fixed, 95%C1	Pavors control Pavors AS
Test for suboroun differences: - Re31017'G allele Study or Subgroup Zaucasian Ja Maksymowych et al., 2003 Subtotal (85%Cl) Total events Total events Total events Subtotal (85%Cl) Total events Total events Subtota (10%Cl) Total events Subtota (10%Cl) Total events Total events Tot	AS groot 252 252 252 252 252 252 252 252 252 25	7. df = 10 10 10 10 10 10 10 10 10 10	1 (P = 0.3 Control g Events 276 276 24 24 24 24 Control Events 240 200 200	0).    <sup>2</sup> = 6 roup Total 976 976 976 66 66 66 66 66 1042   <sup>2</sup> = 79% group Total 488 33	.3% Weight 58.4% 58.4% 41.6% 41.6% 100.0% Weight 94.6% 5.4%	Odds Ratio M-H. Random, 95%C 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10] 1.71 [0.82, 3.59] 0.dds Ratio M-H. Fixed, 95%C1 1.25 [0.96, 1.64] 2.19 [0.83, 5.77]	Pavors control Favors AS
Test for suboroun differences: - <b>Rs31017'G allele</b> Study or Subgroup Zaucasian Total events Total events Total events Subtotal (95%CI) Total events Subtotal (95%CI) Total events Total (95%CI) Total events Sudy or Subgroup 33 Maksymowych et al., 2007 Total (95%CI) Total events Total events Total events Total (95%CI) Total (95%CI) Total events Total (95%CI) Total (95%CI) Total events Total e	AS groot 252 252 252 252 252 252 252 252 252 25	7. df = up Total 766 766 96 96 96 96 96 96 96 96 96	1 (P = 0.3 Control g Events 276 276 276 24 24 24 24 24 Control g 276 276 24 24 24 24 24 24 24 24 24 24	0).   <sup>2</sup> = 6 roup Total 976 976 976 66 66 66 66 66 1042 1042 12 = 79% group Total 33 35	.3% <u>Weight</u> 58.4% 41.6% 41.6% 100.0% <u>Weight</u> 94.6% 5.4%	Odds Ratio M-H. Random, 35%C 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10] 1.71 [0.82, 3.58] Odds Ratio M-H. Fixed, 95%C1 1.25 [0.96, 1.64] 2.19 [0.83, 5.77]	Favors control Favors AS Odds Ratio M-H. Random, 95%CI
Test for suboroup differences: - <b>Rs31017'G allele</b> Study or Subgroup Zaucasian 33 Maksymowych et al., 2003 Subtotal (95%/CI) Total events Heterogeneity: Not applicable Test for overall effect: Z = 2.08 Subtotal (95%/CI) Total events Heterogeneity: Not applicable Test for overall effect: Z = 2.98 Total (95%/CI) Total events Heterogeneity: Tau <sup>2</sup> = 0.23; Chi Test for suboroup differences: N <b>Rs31017'G carrier</b> Study or Subgroup J9 Maksymowych et al., 2003 J9 Yang et al., 2007	AS groot Evonts 252 252 252 252 252 252 252 252 252 25	7. df = up Total 766 766 96 96 96 96 96 96 96 96 96	1 (P = 0.3 Control g Events 276 276 24 24 24 24 24 24 20 Control g 276 24 24 24 24 20 20 20 20 20 21 24 24 26 276 276 24 24 26 276 24 26 276 276 276 276 276 276 276	0)).   <sup>2</sup> = 6 roup <u>Total</u> 976 976 976 66 66 66 1042   <sup>2</sup> = 79% group <u>Total</u> 488 33 521	.3% Weight 58.4% 58.4% 41.6% 41.6% 41.6% 41.6% 100.0%	Odds Ratio M-H. Random, 35%C 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10] 1.71 [0.82, 3.58] Odds Ratio M-H. Fixed, 95%C[ 1.25 [0.96, 1.64] 2.19 [0.83, 5.77] 1.30 [1.01, 1.69]	Pavors control Favors AS Odds Ratio M-H. Random, 95%CI 0.01 0.1 10 1 Favors control Favors AS Odds Ratio M-H. Fixed, 95%CI
Test for suboroun differences: - <b>Rs31017'G allele</b> Study or Subgroup Zaucasian 13 Maksymowych et al., 2003 Subtota (195% CI) Fotal events Heterogeneity: Not applicable fest for overall effect: Z = 2.08 Asian 99 Yang et al., 2007 Subtota (185% CI) Total events Heterogeneity: Not applicable Test for overall effect: Z = 2.98 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0.23; Chi Test for overall effect: Z = 1.24 Test for subgroup. Study or Subgroup. 31 Maksymowych et al., 2007 Total (95% CI) Total (95% CI) Total (95% CI) Total (95% CI) Total (95% CI)	AS groot Events 252 252 252 252 252 252 252 252 252 25	7. df = 10 10 10 10 10 10 10 10 10 10	1 (P = 0.3 Control g <u>Events</u> 276 276 24 24 24 24 24 24 20 Control <u>Events</u> 276 276 24 24 24 24 24 24 24 24 24 24	0)).    <sup>2</sup> = 6 roup <u>Total</u> 976 976 66 66 66 1042    <sup>2</sup> = 79% <u>group</u> <u>Total</u> 488 33 521	.3% <u>Weight</u> 58.4% 41.6% 41.6% 100.0% <u>Weight</u> 94.6% 5.4% 100.0%	Odds Ratio M-H. Random, 95%C 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10] 1.71 [0.82, 3.58] Odds Ratio M-H. Fixed, 95%C 1.25 (0.96, 1.64) 2.19 [0.83, 6.77] 1.30 [1.01, 1.69]	Pavors control Pavors AS
Test for suboroun differences: - <b>Rs31017'G allele</b> Study or Subgroup Caucasian 33 Maksymowych et al., 2003 Subtota (195% CI) Total events Heterogeneity: Not applicable Test for overall effect: Z = 2.08 Asian Dy Yang et al., 2007 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0.23; Chi Test for overall effect: Z = 1.42; Test for subgroup Study or Subgroup Study or Subgroup Stady et al., 2007 Total events Heterogeneity: Tau <sup>2</sup> = 0.23; Chi Test for overall effect: Z = 1.42; Test for subgroup Study or Subgroup D3 Maksymowych et al., 2003 D9 Yang et al., 2007 Total (95% CI) Total effect: Z = 1.17, d.f. Test for overall effect: Z = 2.02 Catageneity: Chi <sup>2</sup> = 1.17, d.f.	AS groups and a second	7, df = 10 10 10 10 10 10 10 10 10 10	1 (P = 0.3 Control g g 276 276 276 24 24 24 24 24 Control Events Control 276 276 24 24 24 24 24 24 24 24 24 24	0).    <sup>2</sup> = 6 roup <u>Total</u> 976 976 66 66 66 1042 <sup>12</sup> = 79% group <u>Total</u> 488 33 521	.3% Weight 58.4% 58.4% 41.6% 41.6% 41.6% 41.8% 100.0%	Odds Ratio M-H. Random, 95%C 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10] 1.71 [0.82, 3.58] Odds Ratio M-H. Fixed, 95%, 164] 1.25 [0.96, 564] 2.19 [0.83, 6.77] 1.30 [1.01, 1.69]	Pavors control Favors AS
Test for suboroup differences: - <b>Rs31017'G allele</b> Study or Subgroup Zaucasian 33 Maksymowych et al., 2003 Subtota (195% CI) Total events Heterogeneity: Not applicable Test for overall effect: Z = 2.08 Asian 39 Yang et al., 2007 Subtota (195% CI) Total events Heterogeneity: Nat applicable Test for overall effect: Z = 2.98 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0.23; Chi Test for subgroup Study or Subgroup 30 Maksymowych et al., 2003 39 Yang et al., 2007 Total (95% CI) Total effect: Z = 2.02 Rs315952''T carrier	AS group: 252 252 252 252 (P = 0.04) 58 58 (P = 0.03) <sup>2</sup> = 4.87, d (P = 0.15) <sup>3</sup> = 4.87, d 4.5 grc 210 37 247 = 1(P = 0.04) <sup>3</sup> = 0.15 <sup>3</sup> = 0	7. df = 10 10 10 10 10 10 10 10 10 10	1 (P = 0.3 Control gr 276 276 24 24 24 24 24 24 24 24 24 24	0).  * = 6 roup Total 976 976 976 66 66 66 1042 * = 79% group Total 33 521	.3% Weight 58.4% 58.4% 41.6% 41.6% 41.6% 41.6% 41.6% 100.0%	Odds Ratio M-H. Random, 95%C 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10] 1.71 [0.82, 3.58] Odds Ratio M-H. Fixed, 95%C 1.25 (0.96, 1.64) 2.19 [0.83, 6.77] 1.30 [1.01, 1.69]	Pavors control Pavors AS
Test for suboroun differences: - <b>Re31017'G allele</b> Study or Subgroup Zaucasian 33 Maksymowych et al., 2003 Subtotal (85% CI) Total events telerogeneity: Not applicable rest for overall effect: Z = 2.08   <b>Kalan</b> 99 Yang et al., 2007 Subtotal (95% CI) Total events telerogeneity: Nat applicable Test for overall effect: Z = 2.98   Total (95% CI) Total events telerogeneity: Tau <sup>2</sup> = 0.23; Chi Test for overall effect: Z = 1.42 Feat for suboroun differences: N <b>R31017'G carrier</b> Study or Subgroup 30 Maksymowych et al., 2007 Total (95% CI) Total events telerogeneity: Chi <sup>2</sup> = 1.17, d.f. Test for overall effect: Z = 2.02 <b>R315952'T carrier</b> All Study or Subgroup All Study or Subgroup	Chi <sup>2</sup> = 1.0 AS group Events. 252 252 (P = 0.04) 58 58 (P = 0.003 310 P = 4.87, G (P = 0.14) AS group AS group = (P = 0.04) 37 74 240 37 74 58 58 58 58 58 58 58 58 58 58	7. df = 10 10 10 10 10 10 10 10 10 10	1 (P = 0.3 Control gr 276 276 24 24 24 24 24 24 24 2003); I Control Events 240 200 200 200 200 200 200 200	0).  P = 6 roup Total 976 976 66 66 1042 P = 79% group Total 33 521 Dup Total V	.3% Weight 58.4% 58.4% 41.6% 41.6% 41.6% 100.0% Weight 100.0% Yeight	Odds Ratio M-H. Random, 95%CC 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10] 1.71 [0.82, 3.58] Odds Ratio M-H. Fixed, 95%CC 1.25 [0.96, 1.64] 2.19 [0.83, 5.77] 1.30 [1.01, 1.69] Odds Ratio	Avors control Favors AS Odds Ratio M-H. Random, 95%Cl M-H. Random, 95%Cl 0.01 0.1 1 10 1 Favors control Favors AS Odds Ratio M-H. Fixed, 95%Cl 0.01 0.1 1 10 1 Favors control Favors AS
Test for suboroup differences: - Rs31017'G allele Study or Subgroup Zaucasian J3 Maksymowych et al., 2003 Subtota (195%CI) Total events -tetorogeneity: Not applicable Test for overall effect: Z = 2.08 Value 14, 2007 Subtota (195%CI) Total events -tetorogeneity: Tau <sup>2</sup> = 0.23; Chi Test for overall effect: Z = 1.42 Test for subgroup J3 Maksymowych et al., 2007 Study or Subgroup J3 Maksymowych et al., 2007 Total (95%CI) Total events -tetorogeneity: Chi <sup>2</sup> = 1.17, d.f. Test for overall effect: Z = 2.02 Rs315952'' Carrier Astion Subgroup Study or Subgroup Ext of Subgroup Study or Subgroup Chi a vents -tetorogeneity: Chi <sup>2</sup> = 1.27, d.f. Test for overall effect: Z = 2.02 Rs315952'' Carrier Astion Subgroup Chi	AS group Events 252 252 252 252 252 252 252 252 252 25	7. df = 10 10 10 10 10 10 10 10 10 10	1 (P = 0.3 Control g g Events 276 276 24 24 24 24 24 24 24 24 24 24	0).  2 = 6 roup Total - 976 976 976 66 66 66 1042 2 <sup>2</sup> = 79% group Total 4 488 33 521 521 521	.3% Weight 58.4% 58.4% 41.6% 41.6% 41.6% 100.0% Weight 100.0% Veight 29.7%	Odds Ratio M-H. Random, 55%C 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10] 1.71 [0.82, 3.58] Odds Ratio M-H. Eixed, 95%CI 1.25 [0.96, 1.64] 2.19 [0.83, 5.77] 1.30 [1.01, 1.69] Odds Ratio M-H. Fixed, 95%CI 1.62 [0.97, 2.70]	Avors control Favors AS  Odds Ratio M-H. Random, 95%CI  Odds Ratio Odds Ratio M-H. Fixed, 95%CI Odds Ratio
Test for suborcup differences:           Rs31017'G allele           Study or Subgroup           Saucasian           Jawasaian           Jawasaian           Jawasayan           Subota(165%CI)           Total events           Heterogeneity: Tau² = 0.23; Chi           Test for overall effect: Z = 1.20;           Study or Suboroup           Ja Maksymowych et al., 2003           Ja Maksymowych et al., 2003           Ja Maksymowych et al., 2003           Total (95%CI)           Total 95%CI)           Total 95%CI           Total 95%CI           Total 95%CI	AS group Events 252 252 (P = 0.04) 58 58 58 58 58 58 58 58 58 58 58 58 58	7. df = 10 10 10 10 10 10 10 10 10 10	1 (P = 0.3 Control gg Events 276 276 276 24 24 24 24 24 24 24 24 24 24	0).  ? = 6 roup Total 976 976 976 66 66 1042 P = 79% group Total 488 33 521 521 521 521 521 521 521 521	.3% Weight 58.4% 58.4% 41.8% 41.8% 41.8% 100.0% Weight 100.0% Veight 29.7% 28.3%	Odds Ratio M-H. Random, 95%CC 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10] 1.71 [0.82, 3.58] Odds Ratio M-H. Fixed, 95%CI 1.25 [0.96, 1.64] Cdds Ratio M-H. Fixed, 95%CI 1.20 [0.97, 2.70] 1.20 [0.97, 2.70]	Pavors control Pavors AS Odds Ratio M-H. Random, 95%Cl 0.01 0.1 1 0 1 Favors control Pavors AS Odds Ratio M-H. Fixed, 95%Cl 0.01 0.1 1 10 1 Favors control Pavors AS Odds Ratio M-H. Fixed, 95%Cl 0.01 0.1 1 10 1 Favors Control Pavors AS Odds Ratio M-H. Fixed, 95%Cl 0.01 0.1 1 10 1 Favors Control Pavors AS Odds Ratio
Test for suboroun differences: - <b>Rs31017'G allele</b> Study or Subgroup Zaucasian 33 Maksymowych et al., 2003 Subtota (195% CI) 701al events 1eterogeneity: Not applicable fest for overall effect Z = 2.08 <b>Value</b> 19' Yang et al., 2007 Subtota (195% CI) 701al events 1eterogeneity: Not applicable 701 (195% CI) 701al events 1eterogeneity: Nat' applicable 701 (195% CI) 701al events 1eterogeneity: Rat' = 0.23; Chi Fest for overall effect: Z = 2.98 701 (195% CI) 701al events 1eterogeneity: Chi <sup>2</sup> = 0.23; Chi Fest for overall effect: Z = 2.98 1014 (195% CI) 701al events 1eterogeneity: Chi <sup>2</sup> = 0.21; 19 Yang et al., 2007 701al (195% CI) 701al events 19 Yang et al., 2007 All Study or Subgroup All Study or Subgroup All 11 Liu et al., 2006 13 Guo et al., 2010		7. df = 10 10 10 10 10 10 10 10 10 10	1 (P = 0.3 Control g g Events 276 276 276 24 24 24 24 24 24 20 20 20 20 215 215 215 215 215 215 215 215	0).  * = 6 roup Total 1 976 976 976 66 66 66 1042 * = 79% group Total 48 33 521 521 521 521 521 521	.3% Weight 58.4% 58.4% 41.6% 41.6% 41.6% 100.0% Weight 100.0% Veight 29.7% 28.3%	Odds Ratio M-H. Random, 95%CC 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10] 1.71 [0.82, 3.59] Odds Ratio M-H. Fixed, 95%CI 1.25 [0.96, 1.64] 2.19 [0.83, 5.77] 1.30 [1.01, 1.69] Odds Ratio M-H. Fixed, 95%CI 1.62 [0.97, 2.70] 1.72 [0.63, 1.99] 1.77 [1.16, 2.69]	Avors control Favors AS Odds Ratio M-H. Random, 95%Cl 0.01 0.1 1 10 1 Favors control Favors AS Odds Ratio M-H. Fixed, 95%Cl M-H. Fixed, 95%Cl M-H. Fixed, 95%Cl
Test for suboroun differences: - Rs31017'G allele Study or Subgroup Zaucasian J3 Maksymowych et al., 2003 Subtota (85%C) Total events -tetorogeneity: Not applicable Test for overall effect: Z = 2.08 Stat Verson (95%C) Total events -tetorogeneity: Not applicable Test for overall effect: Z = 2.98 Total events -tetorogeneity: Tota applicable Test for overall effect: Z = 2.98 Total events -tetorogeneity: Tota applicable Test for overall effect: Z = 2.98 Stat -tetorogeneity: Tota applicable Test for overall effect: Z = 2.98 Total events -tetorogeneity: Tau <sup>2</sup> = 0.23; Chi Test for overall effect: Z = 1.42 Test for suboroun differences: N ts31017'G carrier	AS group Events 252 252 (P = 0.04) 58 58 (P = 0.04) 310 P = 0.003 310 P = 0.003 210 P = 0.003 210 P = 0.003 210 210 210 210 210 210 210 210	7. df = 10 10 10 10 10 10 10 10 10 10	1 (P = 0.3 Control gr 276 276 276 24 24 24 24 24 24 24 20 20 200 20	0).  * = 6 roup Total 976 976 976 976 66 66 1042 * = 79% group Total 488 33 521 568 161 161 5568 1	.3% Weight 58.4% 58.4% 41.6% 41.6% 41.6% 100.0% Weight 100.0% Veight 29.7% 22.3% 22.0% 00.0%	Odds Ratio M-H. Random, 95%C 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10] 1.71 [0.82, 3.58] Odds Ratio M-H. Fixed, 95%CI 1.25 [0.96, 1.64] 2.19 [0.83, 5.77] 1.30 [1.01, 1.69] Odds Ratio M-H. Fixed, 95%CI, 1.62 [0.97, 2.70] 1.77 [1.16, 2063, 1.96] 1.77 [1.16, 2.04]	Pavors control Favors AS Odds Ratio M-H. Random, 95%CI 0.01 0.1 10 1 Favors control Favors AS Odds Ratio M-H. Fixed, 95%CI Favors control Favors AS Odds Ratio M-H. Fixed, 95%CI M-H. Fixed, 95%CI 0.01 0.1 10 1 Favors Sontrol Favors AS
Test for suboroup differences: - <b>Rs31017'G allele</b> Study or Subgroup Jacucasian J3 Maksymowych et al., 2003 Subtota (195%CI) Total events - telerogeneity: Not applicable feest for overall effect: Z = 2.08 Jatian Dy Yang et al., 2007 Subtota (195%CI) Total events - telerogeneity: Tau <sup>2</sup> = 0.23; Chi Test for suboroup differences: N Rs31017'G carrier Study or Subgroup J3 Maksymowych et al., 2007 Total events - telerogeneity: Chi <sup>2</sup> = 1.17, d.f. Test for overall effect: Z = 2.02 Rs315952'T carrier A: Study or Subgroup List for overall effect: Z = 2.02 Rs315952'T carrier A: Study or Subgroup List for overall effect: Z = 2.02 Rs315952'T carrier A: Study or Subgroup List for overall effect: Z = 2.02 Rs315952'T carrier A: Study or Subgroup List for overall effect: Z = 2.02 Rs315952'T carrier A: Study or Subgroup List for overall effect: Z = 2.02 Rs315952'T carrier A: Study or Subgroup List for overall effect: Z = 2.02 Rs315952'T carrier A: Study or Subgroup List for overall effect: Z = 2.02 Rs315952'T carrier A: Study or Subgroup List for overall effect: Z = 2.02 Rs315952'T carrier A: Study or Subgroup List for overall effect: Z = 2.02 Rs315952'T carrier A: Study or Subgroup List for overall effect: Z = 2.02 Rs315952'T carrier A: Study or Subgroup List for overall List et al., 2006 List List et al.	AS group Events 252 252 252 (P = 0.04) 58 58 58 58 58 58 58 58 58 58 58 58 58	7. df = 10 10 10 10 10 10 10 10 10 10	1 (P = 0.3 Control g g 276 276 276 24 24 24 24 24 24 24 24 24 24	0).  P = 6 roup Total - 976 976 976 66 66 66 1042 P = 79% group Total 48 33 521 521 548 185 161 222 568 1	33% Weight 58.4% 58.4% 41.6% 41.6% 41.6% 100.0% Weight 100.0% Yeight 28.3% 42.0% 00.0%	Odds Ratio M-H. Random, 95%C 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 1.24 [1.01, 1.53] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10] 2.67 [1.40, 5.10] 1.71 [0.82, 3.58] Odds Ratio M-H. Fixed, 95%C1 1.26 [0.63, 6.77] 1.30 [1.01, 1.69] Odds Ratio M-H. Fixed, 95%C1 1.20 [0.63, 1.99] 1.77 [1.16, 2.69]	Avors control Favors AS Odds Ratio M-H. Random, 95%Cl 0.01 0.1 0.1 0.1 0.1 10 1 Favors control Favors AS Odds Ratio M-H. Fixed, 95%Cl 0.01 0.1 1 00 1 Favors AS Odds Ratio M-H. Fixed, 95%Cl 0.01 0.1 1 00 1

**Figure 2.** Association of rs30735\*C allele, rs30735\*C carrier, rs31017\*G allele, rs31017\*G carrier, and rs315952\*T carrier with susceptibility to AS. The squares and horizontal lines correspond to the study-specific OR and 95%CI. The diamond represents the summary OR and 95%CI.

©FUNPEC-RP www.funpecrp.com.br

Genetics and Molecular Research 12 (2): 1720-1730 (2013)

## **Publication bias**

All Begger funnel plots appeared to be symmetrical (Figure 3). The Egger test also showed no statistical significance for all evaluations of publication bias (all P > 0.05). The findings of the Egger publication bias test are shown in Table 3.



Figure 3. The Begger funnel plot of publication bias for the association between VNTR, rs419598, rs315952, rs315951, and susceptibility to AS.

Table 3. Evaluation of publication bias by the Egger linear regression test.								
SNP	Coefficient	SE	t	Р	95%CI			
VNTR	1.371	1.257	1.090	0.311	(-1.601, 4.343)			
rs419598	-0.281	2.012	-0.140	0.898	(-6.685, 6.123)			
rs315952	0.241	0.880	0.270	0.810	(-3.543, 4.026)			
rs315951	-3.397	0.096	-35.480	0.018	(-4.613, -2.180)			

SE = standard error; 95%CI = 95% confidence interval. For other abbreviations, see legend to Table 1.

# DISCUSSION

AS is a common, chronic, inflammatory arthritis, and autoimmune disease that mainly affects joints in the spine and the sacroiliac joint in the pelvis, causing eventual fusion of the spine (El Maghraoui, 2011). Its global prevalence ranges from 0 to 1.9%, and is more prevalent in males (Feldtkeller et al., 2003; Baek et al., 2004). Although the exact cause of AS is unknown, we do know that genetic factors play a key role (Stewart and Ralston, 2000). The

Genetics and Molecular Research 12 (2): 1720-1730 (2013)

#### G.X. Jin et al.

HLA-B27 genotype is expressed in about 90% of AS patients, meaning that there is a strong genetic association. However, only 5% of individuals with the HLA-B27-positive genotype develop the disease (Reveille, 2006). Recently, a study conducted in Scotland found an association between the IL-1RN VNTR\*2 allele and AS risk (McGarry et al., 2001). IL-1RN encodes the IL-1Ra protein, a member of the IL-1 cytokine family. This protein inhibits IL-1 $\alpha$  and IL-1 $\beta$  activities and modulates a variety of IL-1-related immune and inflammatory responses (Perrier et al., 2006). Although many relevant studies have indicated an association between IL-1RN SNPs and increased risk of AS (Brown et al., 2000), the results are controversial.

In our meta-analysis, we found 3 SNPs in IL-1RN with strong evidence of association with AS risk after adjustment of multiple testing in the IL-1RN gene, including rs30735, rs31017, and rs315952. Our study showed that rs30735\*C allele/carrier, rs31017\*G carrier, and rs315952\*T carrier have significant associations with AS risk after adjustment for multiple testing. The rs315952\*T carrier was significantly associated with AS risk (OR = 1.54) in 3 studies, but no association was found between the rs315952\*T allele and AS risk. There was also no association between rs315951 and AS risk (all P > 0.05). However, Chou et al. (2006) reported substantially stronger haplotype associations with AS risk by combining rs315952 and rs315951 using linkage disequilibrium statistics, because of under-representation of C homozygosity among AS cases. It is therefore likely that the association of these SNPs with disease reflects linkage disequilibrium with the primary disease locus, as implied by the association with specific inferred haplotypes. In addition, rs30735\*C allele/carrier and rs31017\*G carrier were associated with AS risk with 1.45, 1.73, and 1.30 OR based on 2 published studies (Lin et al., 2006; Maksymowych et al., 2006). Unfortunately, although a recent collaborative study found an association of AS with IL-1RN SNPs and their haplotypes, pooled analyses have not examined the relationship between rs27810\*C allele/carrier, rs31017\*G allele, rs315951\*G allele/carrier, rs315952\*T allele, rs419598\*C allele/carrier, VNTR\*2 allele/carrier with AS risk. Some studies showed that ethnicity might influence AS susceptibility through variations in genetic background and environmental exposure, leading to various gene-gene and gene-environment interactions. In the subgroup analysis based on ethnicity, the rs30735\*C allele/carrier, and the rs31017\*G allele appear to be risk factors for AS in both Caucasians and Asians, while the rs315952\*T carrier was associated with AS susceptibility only in an Asian population. Ethnicity-specific disease associations may arise from differences in genetic linkage disequilibrium structure across populations or due to other unknown environmental or genetic contributors. This influence may only involve susceptibility to and not severity of disease. Thus, meaningful studies in different ethnic backgrounds and in families of AS patients are needed to further establish or adjust this association.

Limitations in our meta-analysis should be addressed. First, because only published studies were included in the meta-analysis, the relevant research articles are few and the sample size was not large. Second, although the funnel plot and the Egger test showed no publication bias, selection bias could have occurred because only studies published in English or Chinese were included. Third, we could remove some variability by performing ethnicity-specific analysis, but there were other sources of heterogeneity, and the genotype distribution deviated from HWE in some studies. In addition, analyses were not conducted for all variants ever evaluated in the context of AS susceptibility. Most important, our meta-analysis was based on unadjusted OR estimates because not all publications presented adjusted ORs and when they did, the ORs were not adjusted by the same potential confounders, such as ethnicity,

Genetics and Molecular Research 12 (2): 1720-1730 (2013)

gender, geographic distribution, etc. Given these results, additional investigation in these areas is needed, and our conclusions should be interpreted cautiously.

In conclusion, this meta-analysis of 13 case-control studies demonstrated that 3 IL-1RN polymorphisms are associated with susceptibility to AS. The rs30735\*C allele/carrier and the rs31017\*G allele are potential risk factors for AS in Caucasians and Asians, while only the rs315952\*T carrier was associated with AS susceptibility in the Asian population. Since only a few studies are available in this field and evidence remains limited, we emphasize the necessity to conduct large studies with adequate methodological quality and proper control of confounding factors to obtain valid results.

## REFERENCES

- Agrawal S, Srivastava R, Sharma B, Pandya S, et al. (2008). IL1RN\*2 allele of IL-1receptor antagonist VNTR polymorphism is associated with susceptibility to ankylosing [corrected] spondylitis in Indian patients. *Clin. Rheumatol.* 27: 573-576.
- Baek HJ, Shin KC, Lee YJ, Kang SW, et al. (2004). Clinical features of adult-onset ankylosing spondylitis in Korean patients: patients with peripheral joint disease (PJD) have less severe spinal disease course than those without PJD. *Rheumatology* 43: 1526-1531.
- Baraliakos X, Listing J, Rudwaleit M, Sieper J, et al. (2008). The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. *Arthritis Res. Ther.* 10: R104.
- Braun J and Sieper J (2007). Ankylosing spondylitis. Lancet 369: 1379-1390.
- Brown MA, Laval SH, Brophy S and Calin A (2000). Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis. Ann. Rheum. Dis. 59: 883-886.
- Chou CT, Timms AE, Wei JC, Tsai WC, et al. (2006). Replication of association of IL1 gene complex members with ankylosing spondylitis in Taiwanese Chinese. *Ann. Rheum. Dis.* 65: 1106-1109.
- Duan Z, Pan F, Zeng Z, Zhang T, et al. (2012). Interleukin-23 receptor genetic polymorphisms and ankylosing spondylitis susceptibility: a meta-analysis. *Rheumatol. Int.* 32: 1209-1214.
- El Maghraoui A (2011). Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. *Eur. J. Intern. Med.* 22: 554-560.
- Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, et al. (2003). Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. *Rheumatol. Int.* 23: 61-66.
- Guo ZS, Li C, Lin ZM, Huang JX, et al. (2010). Association of IL-1 gene complex members with ankylosing spondylitis in Chinese Han population. Int. J. Immunogenet. 37: 33-37.

Higgins JP and Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat. Med. 21: 1539-1558.

- Kim TH, Stone MA, Rahman P, Yoo DH, et al. (2005). Interleukin 1 and nuclear factor-kappaB polymorphisms in ankylosing spondylitis in Canada and Korea. J. Rheumatol. 32: 1907-1910.
- Laval SH, Timms A, Edwards S, Bradbury L, et al. (2001). Whole-genome screening in ankylosing spondylitis: evidence of non-MHC genetic-susceptibility loci. Am. J. Hum. Genet. 68: 918-926.
- Lin L, Chen WG and Hu FP (2006). Interleukin-1R and interleukin-1 receptor antagonist gene polymorphisms in Hu'nan Han nationoality ankylosing spondylitis patient. *Clin. J. Rheumatol.* 10: 726-728.
- Liu H, Kong XD, Cai Q, Lu HQ, et al. (2008). The effect of single nucleotide polymorphism in interleukin-1 gene on the susceptibility of ankylosing spondylitis in Chinese Han population. *Chin. J. Rheumatol.* 12: 304-308.
- Maksymowych WP, Reeve JP, Reveille JD, Akey JM, et al. (2003). High-throughput single-nucleotide polymorphism analysis of the IL1RN locus in patients with ankylosing spondylitis by matrix-assisted laser desorption ionizationtime-of-flight mass spectrometry. *Arthritis Rheumatol.* 48: 2011-2018.
- Maksymowych WP, Rahman P, Reeve JP, Gladman DD, et al. (2006). Association of the IL1 gene cluster with susceptibility to ankylosing spondylitis: an analysis of three Canadian populations. *Arthritis Rheumatol.* 54: 974-985.
- McGarry F, Neilly J, Anderson N, Sturrock R, et al. (2001). A polymorphism within the interleukin 1 receptor antagonist (IL-1Ra) gene is associated with ankylosing spondylitis. *Rheumatology* 40: 1359-1364.
- Peloso PM, Gammaitoni A, Smugar SS, Wang H, et al. (2011). Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitis. *BMC Musculoskelet. Disord.* 12: 165.

Perrier S, Darakhshan F and Hajduch E (2006). IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?

Genetics and Molecular Research 12 (2): 1720-1730 (2013)

FEBS Lett. 580: 6289-6294.

- Peters JL, Sutton AJ, Jones DR, Abrams KR, et al. (2006). Comparison of two methods to detect publication bias in metaanalysis. JAMA 295: 676-680.
- Reveille JD (2006). Major histocompatibility genes and ankylosing spondylitis. Best. Pract. Res. Clin. Rheumatol. 20: 601-609.
- Reveille JD, Sims AM, Danoy P, Evans DM, et al. (2010). Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. *Nat. Genet.* 42: 123-127.
- Sims AM, Timms AE, Bruges-Armas J, Burgos-Vargas R, et al. (2008). Prospective meta-analysis of interleukin 1 gene complex polymorphisms confirms associations with ankylosing spondylitis. Ann. Rheum. Dis. 67: 1305-1309.
- Stewart TL and Ralston SH (2000). Role of genetic factors in the pathogenesis of osteoporosis. J. Endocrinol. 166: 235-245.
- Timms AE, Crane AM, Sims AM, Cordell HJ, et al. (2004). The interleukin 1 gene cluster contains a major susceptibility locus for ankylosing spondylitis. *Am. J. Hum. Genet.* 75: 587-595.
- van der Paardt M, Crusius JB, Garcia-Gonzalez MA, Baudoin P, et al. (2002). Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms in ankylosing spondylitis. *Rheumatology* 41: 1419-1423.
- Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, et al. (2007). Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. *Epidemiology* 18: 805-835.
- Yang Y, Su ZW, Ma WS, Cai AJ, et al. (2007). Single nucleotide polymorphism of IL-1RN and TNF-α in ankylosing spondylitis. J. Trop. Med. 7: 948-951.
- Zhang L, Liu JL, Zhang YJ and Wang H (2011). Association between HLA-B\*27 polymorphisms and ankylosing spondylitis in Han populations: a meta-analysis. *Clin. Exp. Rheumatol.* 29: 285-292.
- Zintzaras E and Ioannidis JP (2005). Heterogeneity testing in meta-analysis of genome searches. *Genet. Epidemiol.* 28: 123-137.

Genetics and Molecular Research 12 (2): 1720-1730 (2013)